Yi Lu

The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2

George W. Sledge, Masakazu Toi, Patrick Neven et al. · JAMA Oncology · 2019 · 941 citations · Full text

MONARCH plus: abemaciclib plus endocrine therapy in women with HR+/HER2– advanced breast cancer: the multinational randomized phase III study

Qing Yuan Zhang, Tao Sun, Yong Yin et al. · Therapeutic Advances in Medical Oncology · 2020 · 102 citations · Full text

Optimizing a 3D Culture System to Study the Interaction between Epithelial Breast Cancer and Its Surrounding Fibroblasts

Liyuan Li, Yi Lu · Journal of Cancer · 2011 · 66 citations · Full text

Tissue Engineering, Breast Oncology, Engineering +21

Updated efficacy, safety, & PD-L1 status of patients with HR+, HER2- metastatic breast cancer administered abemaciclib plus pembrolizumab.

Sara M. Tolaney, Peter Kabos, Maura N. Dickler et al. · Journal of Clinical Oncology · 2018 · 40 citations

Breast Oncology, Pd-l1 Inhibitors, Immunology +18

nextMONARCH: Abemaciclib Monotherapy or Combined With Tamoxifen for Metastatic Breast Cancer

Erika Hamilton, Javier Cortés, Özgür Özyılkan et al. · Clinical Breast Cancer · 2020 · 39 citations

Metastatic Breast Cancer, Oncology, Breast Oncology +8